Pediatric combined formulation DTaP–IPV/Hib vaccine

References

• Diphtheria. In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (10th, 2nd printing Edition). Atkinson W, Hamborsky J, McIntyre L, Wolfe S (Eds). Public Health Foundation, Washington, DC, USA, 59–70 (2008).
   Google Scholar
• Dittmann S, Wharton M, Vitek C et al. Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J. Infect. Dis.181(Suppl. 1), S10–S22 (2000).
   Web of Science ®Google Scholar
• Galazka A. Implications of the diphtheria epidemic in the Former Soviet Union for immunization programs. J. Infect. Dis.181(Suppl. 1), S244–S228 (2000).
   PubMedGoogle Scholar
• Vitek CR. Diphtheria. Curr. Top. Microbiol. Immunol.304, 71–94 (2006).
   PubMed Web of Science ®Google Scholar
• Brook I. Tetanus in children. Pediatr. Emerg. Care. Jan. 20(1), 48–51 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Tetanus surveillance – United States, 1995–1997. MMWR Surveill. Summ.47(2), 1–13 (1998).
   PubMedGoogle Scholar
• CDC. Progress toward global eradication of poliomyelitis, 2002. MMWR Morb. Mortal. Wkly Rep.52(16), 366–369 (2003).
   PubMedGoogle Scholar
• CDC. Progress toward poliomyelitis eradication – Nigeria, January 2007 –August 12, 2008. MMWR Morb. Mortal. Wkly Rep.57(34), 942–946 (2008).
   PubMedGoogle Scholar
• Galil K, Singleton R, Levine OS et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J. Infect. Dis.179(1), 101–106 (1999).
   PubMed Web of Science ®Google Scholar
• McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet361(9368), 1521–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Bettinger JA, Halperin SA, Law B, Bortolussi R. Ongoing control of Haemophilus influenzae type b infections in Canadian children, 2004–2007. Pediatr. Infect. Dis. J.27(8), 755–757 (2008).
   PubMed Web of Science ®Google Scholar
• Scheifele D, Halperin S, Law B et al. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001–2003. CMAJ172(1), 53–56 (2005).
   PubMed Web of Science ®Google Scholar
• Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur. J. Clin. Microbiol. Infect. Dis.19(2), 77–88 (2000).
   PubMed Web of Science ®Google Scholar
• Guris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin. Infect. Dis.28(6), 1230–1237 (1999).
   PubMed Web of Science ®Google Scholar
• Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics.115(5), 1422–1427 (2005).
   PubMed Web of Science ®Google Scholar
• Englund JA, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J. Infect. Dis.166(6), 1436–1441 (1992).
   PubMed Web of Science ®Google Scholar
• Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr. Respir. Rev.9(3), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou F, Santoli J, Messonnier ML et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch. Pediatr. Adolesc. Med.159(12), 1136–1144 (2005).
   PubMedGoogle Scholar
• CDC. Recommended childhood and adolescent immunization schedule – United States. MMWR Morb. Mortal. Wkly Rep.55(51–52), Q1–Q3 (2005).
   Google Scholar
• CDC. Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR Morb. Mortal. Wkly Rep.56, 1318–1320 (2007).
   PubMedGoogle Scholar
• Prevots DR, Burr RK, Sutter RW, Murphy TV, Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.49(RR-5), 1–22 (2000).
   PubMedGoogle Scholar
• Scheifele DW, Halperin SA, Rubin E et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum. Vaccin.1(5), 80–186 (2005).
   PubMedGoogle Scholar
• Marshall GS, Happe LE, Lunacsek OE et al. Use of combination vaccines is associated with improved coverage rates. Pediatr. Infect. Dis. J.26(6), 496–500 (2007).
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep.33(ACS-1), 1–14 (2007).
   Google Scholar
• Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr. Infect. Dis. J.24(6 Suppl.), S117–S126 (2005).
   Web of Science ®Google Scholar
• Halperin SA, Eastwood B, Barreto L et al. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2–6 months old. Scand. J. Infect. Dis.27(3), 279–287 (1995).
   Google Scholar
• Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med.334(6), 349–355 (1996).
   PubMed Web of Science ®Google Scholar
• Pentacel® prescribing information. Sanofi pasteur Inc., June (2008).
   Google Scholar
• Halperin SA, Barreto L, Eastwood BJ, Law B, Roberts EA. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch. Pediatr. Adolesc. Med.148(11), 1220–1224 (1994).
   PubMedGoogle Scholar
• Halperin SA, Eastwood BJ, Barreto L et al. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine14(8), 767–772 (1996).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Meade BD, Decker MD et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics Sep. 96(3 Pt 2), 548–557 (1995).
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics96(3 Pt 2), 557–566 (1995).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Deloria MA, Rennels MB et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics100(5), 772–788 (1997).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Barreto L, Friesen B, Meekison W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch. Pediatr. Adolesc. Med.148(5), 495–502 (1994).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Mills E, Barreto L, Pim C, Eastwood BJ. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J.14(9), 792–797 (1995).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Scheifele D, Barreto L et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr. Infect. Dis. J.18(9), 772–779 (1999).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Edwards KM, Anderson EL et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics105(1), e11 (2000).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Barreto L, Eastwood BJ, Medd L, Guasparini R, Mills E. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine15(3), 295–300 (1997).
   Google Scholar
• Halperin SA, Davies HD, Barreto L et al. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J. Pediatr.130(4), 525–531 (1997).
   PubMed Web of Science ®Google Scholar
• Mills E, Gold R, Thipphawong J et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine16(6), 576–585 (1998).
   PubMed Web of Science ®Google Scholar
• Lee CY, Thipphawong J, Huang LM et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics103(1), 25–30 (1999).
   PubMed Web of Science ®Google Scholar
• Noriega F, Tsang P, Jemiolo D, Voloshen T, Greenberg DP. Immunogenicity of a four-dose series of DTaP–IPV/PRP-T vaccine (PentacelTM). The Pentacel Investigators Study Group. Presented at: 5th Pediatric Infectious Disease Conference. Napa, CA, USA, 9–11 October 2005 (Abstract 9).
   Google Scholar
• Noriega F, Tomovici A, Jemiolo D, Greenberg DP. Safety and immunogenicity comparison of a fourth dose of DTaP–IPV/PRP-T (PentacelTM) to the separate administration of DAPTACEL® and ActHIB®. P3T06 Study Group. Presented at: 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, USA, 6–9 October 2005 (Abstract 985).
   Google Scholar
• Herz A, Black S, Shinefield H, Noriega F, Greenberg D. Safety of a DTaP–IPV/PRP-T (PentacelTM) administered at 2, 4, 6, and 15 to 18 months of age. Presented at: Pediatric Academy Societies Annual Meeting. Washington, DC, USA, 14–17 May 2005 (Abstract 1388).
   Google Scholar
• Edwards KM, Tsang P, Noriega F. Safety and immunogencity of DTaP–IPV-PRP-T (PentacelTM) co-administered with pneumococcal conjugate vaccine (Prevnar®) at 2, 4, and 6 months of age. For the M5A03 Study Group. Presented at: 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, USA, 6–9 October 2005 (Abstract 984).
   Google Scholar
• Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine24(12), 2057–2064 (2006).
   PubMed Web of Science ®Google Scholar
• Noriega F, Greenberg DP, Tsang P. Effect of pneumococcal conjugate vaccine (PCV-7) on antibody responses to concomitantly administered PentacelTM (DTaP–IPV/PRP-T) or licensed-equivalent vaccines. Pentacel Vaccine Study Group. Presented at: 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, USA, 6–9 October 2005 (Abstract 981).
   Google Scholar
• Halperin SA, McDonald J, Samson L et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin. Invest. Med.25(6), 243–251 (2002).
   PubMed Web of Science ®Google Scholar
• Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Use of lidocaine–prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria–tetanus–acellular pertussis-inactivated poliovirus–Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr. Infect. Dis. J.21(5), 399–405 (2002).
   PubMed Web of Science ®Google Scholar
• CDC. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and Haemophilus b conjugate vaccine and guidance for use in infants and children. MMWR Morb. Mortal. Wkly Rep.57(39), 1079–1080 (2008).
   PubMedGoogle Scholar
• Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr. Infect. Dis. J.26(1), 31–35 (2007).
   Google Scholar
• Kalies H, Grote V, Siedler A, Grondahl B, Schmitt HJ, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine26(20), 2545–2552 (2008).
   PubMed Web of Science ®Google Scholar
• Partridge S, Yeh SH. Clinical evaluation of a DTaP–HepB–IPV combined vaccine. Am. J. Manag. Care.9(1 Suppl.), S13–S22 (2003).
   Google Scholar
• Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am. J. Manag. Care.13(9), 506–512 (2007).
   PubMed Web of Science ®Google Scholar
• CDC. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX™) for use in infants. MMWR Morb. Mortal. Wkly Rep.52(10), 203–204 (2003).
   PubMedGoogle Scholar
• Halperin SA, Scheifele D, Mills E et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine21(19–20), 2298–2306 (2003).
   PubMed Web of Science ®Google Scholar
• Notifiable Diseases Reporting System. Age-specific rates of pertussis in Canada, 1989–2005. Public Health Agency of Canada, Canada (2008).
   Google Scholar
• Notifiable Diseases Reporting System. Invasive Haemophilus influenzae type b disease in Canada, 1990–2005. Public Health Agency of Canada, Canada (2008).
   Google Scholar